A Phase 2 interventional study of Alpelisib and Fulvestrant in Advanced Breast Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 1 site in Sweden. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-06-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing alpelisib in Breast Neoplasms — 3 open to participants now, 12 under way, 2 of them phase 3. Alpelisib · Breast Neoplasms.
Among the 38 studies testing alpelisib in Breast Neoplasms, this one is the 37th largest by enrollment, is one of 4 that started in 2022, is one of 15 in phase 2, and was the 27th registered.
14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →3 of the 38 studies testing alpelisib in Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
The Methodist Hospital Research Institute · Sites in United States
Ages 18+
Novartis Pharmaceuticals
By country, each count listing its studies:
Alpelisib: first FDA approval 2019 (PIQRAY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, alpelisib is the treatment under test here. Read study by study →
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 19 · Phase 3 5
First in 2010; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2 is below the median of 72 across 10,910 interventional studies indexed under Breast Neoplasms.
Median enrollment 44 across the 38 interventional studies. Of the 25 that completed or were terminated, 10 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 150th largest by enrollment of the 155 interventional ones that give a count, is one of 10 that started in 2022, is one of 39 in phase 2, and was the 146th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
7 of the studies testing alpelisib in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05038735Phase 3Novartis PharmaceuticalsStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. | 2027-01-28 |
| NCT04208178Phase 3Novartis PharmaceuticalsStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | 2027-02-26 |
| NCT05660083The Methodist Hospital Research InstituteAlpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | 2026-12-01 |
| NCT04544189Novartis PharmaceuticalsStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer | 2027-01-29 |
| NCT01872260Novartis PharmaceuticalsStudy of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | 2027-02-26 |
Add all 7 to your calendar (.ics) → With an account.
Among the 38 studies testing alpelisib in Breast Neoplasms, from their registry updates:
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The study was designed to identify and register practical observations and experiences in connection with planning and implementing decentralized, patient-centered clinical trials at a geographic distance with virtual elements.
The purpose of this open-label, single arm, multi-center, Phase II interventional pilot trial was to evaluate if a decentralized clinical trial (DCT) using a telemedicine platform offers a satisfactory, safe and suitable management for HR-positive/HER2-negative participants with advanced breast cancer harboring a PIK3CA mutation and treated with alpelisib plus fulvestrant. The trial utilized a hybrid DCT approach to reduce participant burden by bringing visits, services, and supplies closer to them.
The planned duration of treatment was 12 cycles of 28 days. Participants could discontinue treatment earlier due to unacceptable toxicity, disease progression and/or decision made at the discretion of the investigator or the participant.
On-site visits occurred during screening, at Cycle 1 Day 1 (baseline), and at end-of-trial. Visits at the local oncologist practice were planned on Day 1 of Cycle 2, Cycle 4, Cycle 7, and Cycle 10. Other visits were performed by a district nurse, either at home or at the local oncologist's practice, depending on the participant's preference.
During the on-site visit on Cycle 1, Day 1, participants were trained on using the telemedicine platform, and other monitoring devices used during remote participation: a glucometer and a smartphone with the telemedicine application installed. Study treatment was also initiated during this visit. The participants were then transitioned to remote participation enabled by the telemedicine platform with support of local healthcare providers (local oncologist, district nurse, or other qualified healthcare professional) under the investigator's oversight.
Discontinuation of remote participation was not a reason for trial termination. Participants who did not wish to continue with remote participation had the option to attend on-site visits.
The study planned to enroll approximately 20 participants, however the study was terminated prematurely with only 2 participants enrolled. The decision to terminate the study was due to delays during the start-up period and due to low enrollment. The decision to terminate was not related to any potential safety concern with alpelisib.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were administered alpelisib at a daily dose of 300 mg for 12 cycles of 28 days and fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and Day 1 of each subsequent cycle up to Cycle 12. Pre-menopausal women also received goserelin at a dose of 3.6 mg on Day 1 of each cycle.
Drug: Alpelisib · Drug: Fulvestrant · Drug: Goserelin
Participants received a daily oral dose of 300 mg of alpelisib film-coated tablets for a total of 12 cycles, with each cycle lasting 28 days.
Also known as: BYL719
Participants were administered fulvestrant at a dose of 500 mg via intramuscular injection on Cycle 1 Day 1 and Cycle 1 Day 15, and on Day 1 of each 28-day cycle thereafter until Cycle 12.
Pre-menopausal women were administered a dose of 3.6 mg of goserelin injection via intramuscular route, beginning on Cycle 1 Day 1. Subsequently, the same dose was administered on Day 1 of each 28-day cycle throughout the study.
Participant Satisfaction Assessed Through the Trial Feedback Questionnaire (TFQ)
The TFQ was designed to capture the patient's experience during a clinical trial. The questionnaire consisted of 23 questions that assessed various aspects of the trial experience. Each question in the TFQ scored on a scale ranging from 1 (representing the worst response) to 5 (representing the best response). To calculate the total score, the scores obtained from each of the 23 questions were summed up. The resulting sum represented the participant's total score, which could ranged from 23 (indicating the lowest possible score) to 115 (indicating the highest possible score).
Time frame: Baseline, and on Day 1 of Cycle 4 and 7. Cycle= 28 days
Patient Retention on the Decentralized Clinical Trial (DCT) Approach
Patient retention on the DCT approach was calculated as the percentage of participants on remote monitoring for participants still on treatment
Time frame: At 3 and 6 months
Number of Unscheduled In-clinic Visits
Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits was evaluated
Time frame: From the date of the first study treatment up to the end of study, assessed up to 6 months
Number of Unscheduled In-clinic Visits Because of Safety Reasons
Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits that were prompted by safety reasons was evaluated
Time frame: From the date of the first study treatment up to the end of study, assessed up to 6 months
Number of Unscheduled In-clinic Visits Per Participant in the Study
Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits per participants was evaluated
Time frame: From the date of the first study treatment up to the end of study, assessed up to 6 months
Number of Participants Who Discontinue Treatment Due to Adverse Events (AEs)
An AE refers to any untoward medical occurrence, such as an unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease. The number of participants who discontinued the treatment due to adverse events was evaluated
Time frame: From the date of the first study treatment up to the end of treatment, assessed up to 6 months
Number of Participants With Dose Reductions/Interruptions for Alpelisib
Number of participants with dose reductions and interruptions for alpelisib
Time frame: From the date of the first study treatment up to the end of treatment, assessed up to 6 months
Number of Participants With Adverse Events of Special Interest (AESIs)- Hyperglycemia, Rash and Diarrhea
AESIs (Adverse Events of Special Interest) are defined as events, whether serious or non-serious, that are of scientific and medical concern specific to the sponsor's product or program. These events may require ongoing monitoring and communication by the investigator to the sponsor. For this study, the following AESIs were defined: hyperglycemia, rash, and diarrhea. The number of participants experiencing these events per the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 was evaluated.
Time frame: From the date of the first study treatment up to the end of study, assessed up to 6 months
Number of Participants With Adverse Events (AEs) Leading to In-clinic Visits
An AE refers to any untoward medical occurrence, such as an unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease. The number of participants with AEs per the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 leading to in-clinic visits was assessed.
Time frame: From the date of the first study treatment up to the end of study, assessed up to 6 months
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
The EORTC QLQ-C30 questionnaire contained 30 items and was composed of both multi-item scales and single item measures. These included five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and a global health status/quality of life (QoL) scale. All of the scales and single items ranged from 0 to 100. A high scale score represented a higher response level. Thus, a high score for a functional scale indicated a high/healthy level of functioning, a high score for the QoL indicated high QoL, but a high score for a symptom scale/single item indicated a high level of symptomatology/problems. The EORTC QLQ-C30 scores for all functional and symptom scales were evaluated
Time frame: Baseline, and on Day 1 of Cycle 4, and 7 and end of treatment, assessed up to 6 months. Cycle= 28 days
EuroQol 5-Dimension 5-Level (EQ-5D-5L)- Visual Analog Scale (VAS) Score
The 5-level EQ-5D (EQ-5D-5L) questionnaire is a standardized measure of health status. The EQ-5D descriptive system comprises of the 5 following dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Along with the five dimensions of health, the EQ-5D-5L includes a VAS where respondents rate their overall health status on a scale from 0 to 100, where 0 represents the worst possible health state and 100 represents the best possible health state. The EQ-5D-5L VAS scores were evaluated
Time frame: Baseline, and on Day 1 of Cycle 4, and 7 and end of treatment, assessed up to 6 months. Cycle= 28 days
Brief Pain Inventory Short Form (BPI-SF) Scores
The BPI-SF was a questionnaire used to assess pain intensity and interference with daily activities. The Pain Severity Subscale included four questions asking individuals to rate their pain intensity on a scale from 0 to 10, with higher scores indicating more severe pain. The Pain Interference Subscale consisted of seven items that assessed how pain had interfered with activities, rated on the same scale. Both subscales had a total score range of 0 to 10, with higher scores indicating more significant pain or interference.
Time frame: Baseline, and on Day 1 of Cycle 4, and 7 and end of treatment, assessed up to 6 months. Cycle= 28 days
Number of Participants With Progression-free Survival (PFS) According to RECIST 1.1
The number of participants with PFS was defined as the count of participants who did not experience disease progression or death due to any cause during the study. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 based on local radiology review.
Time frame: Up to 6 months
The study was conducted in 1 center from Sweden
| Milestone | Alpelisib + Fulvestrant |
|---|---|
| Started | 2 |
| Completed | 0 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Study terminated by sponsor | 1 |
The TFQ was designed to capture the patient's experience during a clinical trial. The questionnaire consisted of 23 questions that assessed various aspects of the trial experience. Each question in the TFQ scored on a scale ranging from 1 (representing the worst response) to 5 (representing the best response). To calculate the total score, the scores obtained from each of the 23 questions were summed up. The resulting sum represented the participant's total score, which could ranged from 23 (indicating the lowest possible score) to 115 (indicating the highest possible score).
| Score on a Scale | Alpelisib + Fulvestrant |
|---|---|
| Baseline | 99.5 (92 to 107) |
| Cycle 4 Day 1 | 89 |
| Cycle 7 Day 1 | 98 |
Patient retention on the DCT approach was calculated as the percentage of participants on remote monitoring for participants still on treatment
| Participants | Alpelisib + Fulvestrant |
|---|---|
| 3 months | 1 |
| 6 months | 1 |
Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits was evaluated
| Visits | Alpelisib + Fulvestrant |
|---|---|
| Number of Unscheduled In-clinic Visits | 0 |
Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits that were prompted by safety reasons was evaluated
| Visits | Alpelisib + Fulvestrant |
|---|---|
| Number of Unscheduled In-clinic Visits Because of Safety Reasons | 0 (0 to 0) |
Unscheduled in-clinic visits were defined as visits that were originally intended to be conducted remotely but were ultimately carried out on-site, or visits that were not originally scheduled but took place on-site or at the local oncologist's (regional hospital). The total number of unscheduled in-clinic visits per participants was evaluated
| Visits per participant | Alpelisib + Fulvestrant |
|---|---|
| Number of Unscheduled In-clinic Visits Per Participant in the Study | 0 (0 to 0) |
An AE refers to any untoward medical occurrence, such as an unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease. The number of participants who discontinued the treatment due to adverse events was evaluated
| Participants | Alpelisib + Fulvestrant |
|---|---|
| Number of Participants Who Discontinue Treatment Due to Adverse Events (AEs) | 1 |
Number of participants with dose reductions and interruptions for alpelisib
| Participants | Alpelisib + Fulvestrant |
|---|---|
| Dose interruptions | 1 |
| Dose reductions | 1 |
AESIs (Adverse Events of Special Interest) are defined as events, whether serious or non-serious, that are of scientific and medical concern specific to the sponsor's product or program. These events may require ongoing monitoring and communication by the investigator to the sponsor. For this study, the following AESIs were defined: hyperglycemia, rash, and diarrhea. The number of participants experiencing these events per the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 was evaluated.
| Participants | Alpelisib + Fulvestrant |
|---|---|
| Diarrhea | 1 |
| Hyperglycaemia | 2 |
| Rash | 0 |
An AE refers to any untoward medical occurrence, such as an unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease. The number of participants with AEs per the Common Terminology Criteria for Adverse Events (CTCAE) v4.03 leading to in-clinic visits was assessed.
| Participants | Alpelisib + Fulvestrant |
|---|---|
| Number of Participants With Adverse Events (AEs) Leading to In-clinic Visits | 0 |
The EORTC QLQ-C30 questionnaire contained 30 items and was composed of both multi-item scales and single item measures. These included five functional scales (physical, role, emotional, cognitive, and social functioning), three symptom scales (fatigue, nausea/vomiting, and pain), six single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and a global health status/quality of life (QoL) scale. All of the scales and single items ranged from 0 to 100. A high scale score represented a higher response level. Thus, a high score for a functional scale indicated a high/healthy level of functioning, a high score for the QoL indicated high QoL, but a high score for a symptom scale/single item indicated a high level of symptomatology/problems. The EORTC QLQ-C30 scores for all functional and symptom scales were evaluated
| Score on a Scale | Alpelisib + Fulvestrant |
|---|---|
| QoL- Baseline | 75 (67 to 83) |
| QoL- Cycle 4 Day 1 | 83 |
| QoL- Cycle 7 Day 1 | 92 |
| QoL- End of Treatment | 75 (67 to 83) |
| Physical Functioning- Baseline | 90 (80 to 100) |
| Physical Functioning- Cycle 4 Day 1 | 93 |
| Physical Functioning- Cycle 7 Day 1 | 100 |
| Physical Functioning-End of Treatment | 86.5 (80 to 93) |
| Role Functioning- Baseline | 91.5 (83 to 100) |
| Role Functioning- Cycle 4 Day 1 | 100 |
| Role Functioning- Cycle 7 Day 1 | 100 |
| Role Functioning-End of Treatment | 83.5 (67 to 100) |
| Emotional Functioning- Baseline | 71 (67 to 75) |
| Emotional Functioning- Cycle 4 Day 1 | 83 |
| Emotional Functioning- Cycle 7 Day 1 | 92 |
| Emotional Functioning- End of treatment | 83 (83 to 83) |
| Cognitive Functioning- Baseline | 91.5 (83 to 100) |
| Cognitive Functioning- Cycle 4 Day 1 | 100 |
| Cognitive Functioning- Cycle 7 Day 1 | 100 |
| Cognitive Functioning- End of treatment | 75 (67 to 83) |
| Social Functioning- Baseline | 91.5 (83 to 100) |
| Social Functioning- Cycle 4 Day 1 | 100 |
| Social Functioning- Cycle 7 Day 1 | 100 |
| Social Functioning- End of treatment | 91.5 (83 to 100) |
| Fatigue- Baseline | 22 (0 to 44) |
| Fatigue- Cycle 4 Day 1 | 22 |
| Fatigue- Cycle 7 Day 1 | 0 |
| Fatigue- End of treatment | 33 (22 to 44) |
| Nausea/vomiting- Baseline | 0 (0 to 0) |
| Nausea/vomiting- Cycle 4 Day 1 | 17 |
| Nausea/vomiting- Cycle 7 Day 1 | 0 |
| Nausea/vomiting- End of treatment | 0 (0 to 0) |
| Pain- Baseline | 8.5 (0 to 17) |
| Pain- Cycle 4 Day 1 | 0 |
| Pain- Cycle 7 Day 1 | 0 |
| Pain- End of treatment | 16.5 (0 to 33) |
The 5-level EQ-5D (EQ-5D-5L) questionnaire is a standardized measure of health status. The EQ-5D descriptive system comprises of the 5 following dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Along with the five dimensions of health, the EQ-5D-5L includes a VAS where respondents rate their overall health status on a scale from 0 to 100, where 0 represents the worst possible health state and 100 represents the best possible health state. The EQ-5D-5L VAS scores were evaluated
| Score on a scale | Alpelisib + Fulvestrant |
|---|---|
| Baseline | 80 (75 to 85) |
| Cycle 4 Day 1 | 93 |
| Cycle 7 Day 1 | 95 |
| End of treatment | 82.5 (70 to 95) |
The BPI-SF was a questionnaire used to assess pain intensity and interference with daily activities. The Pain Severity Subscale included four questions asking individuals to rate their pain intensity on a scale from 0 to 10, with higher scores indicating more severe pain. The Pain Interference Subscale consisted of seven items that assessed how pain had interfered with activities, rated on the same scale. Both subscales had a total score range of 0 to 10, with higher scores indicating more significant pain or interference.
| Score on a scale | Alpelisib + Fulvestrant |
|---|---|
| Pain severity- Baseline | 1.63 (1.25 to 2.00) |
| Pain severity- Cycle 4 Day 1 | 0 |
| Pain severity- Cycle 7 Day 1 | 0.75 |
| Pain severity- End of treatment | 1.13 (0.00 to 2.25) |
| Pain interference- Baseline | 0.79 (0.00 to 1.57) |
| Pain interference- Cycle 4 Day 1 | 0 |
| Pain interference- Cycle 7 Day 1 | 0 |
| Pain interference- End of treatment | 1.07 (0 to 2.14) |
The number of participants with PFS was defined as the count of participants who did not experience disease progression or death due to any cause during the study. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 based on local radiology review.
| Participants | Alpelisib + Fulvestrant |
|---|---|
| Number of Participants With Progression-free Survival (PFS) According to RECIST 1.1 | 2 |
Collected over From start up to end of study, assessed up to 6 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Alpelisib + Fulvestrant | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Event | Alpelisib + Fulvestrant |
|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 2/2 |
| FatigueGeneral disorders | 2/2 |
| NauseaGastrointestinal disorders | 2/2 |
| Abdominal painGastrointestinal disorders | 1/2 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/2 |
| Decreased appetiteMetabolism and nutrition disorders | 1/2 |
| DiarrheaGastrointestinal disorders | 1/2 |
| Dry mouthGastrointestinal disorders | 1/2 |
| GastritisGastrointestinal disorders | 1/2 |
| StomatitisGastrointestinal disorders | 1/2 |
| Age, Continuous(Years) | Alpelisib + Fulvestrant |
|---|---|
| Mean | 54 ± 0 |
| Sex/Gender, Customized(Participants) | Alpelisib + Fulvestrant |
|---|---|
| Unknown | 2 |
| Race and Ethnicity Not Collected(Participants) | Alpelisib + Fulvestrant |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Mar 2022 to primary completion in Sep 2022, 6 months.
Results were first posted in Feb 2024, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alpelisib